ArticleInternational journal of molecular sciences2025
Inflammation and Cognition in Bipolar Disorder: Diverging Paths of Interleukin-6 and Outcomes.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Immune dysregulation and neuroinflammation in bipolar disorder: Pathophysiological insights and therapeutic perspectives.Brain, behavior, & immunity - health · 2026Review
- Special Issue "Translating Molecular Psychiatry: From Biomarkers to Personalized Therapies".International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Bipolar disorder (BD) may present with neurocognitive dysfunction due to inflammatory alterations through different biological pathways. However, findings are not consistent regarding the patterns of neurocognitive dysfunction and elevation of inflammatory biomarkers during the different mood phases. Therefore, we aimed to determine associations between inflammatory biomarkers, neurocognitive functioning, and clinical outcomes in patients with BD in euthymia. We conducted a cross-sectional study including 109 adults. Serum levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), neurocognitive parameters (ACER), number of suicide attempts (SA), and hospitalizations (NH) were measured. We found negative and moderate correlations between IL-6 and ACER total score, language, visuospatial abilities, and orientation/attention. There was a positive and moderate correlation between IL-6 and NH. IL-6 significantly predicted ACER total score, language, memory, orientation/attention, visuospatial abilities, and NH. Overall, IL-6 had an inverse association with neurocognition and clinical variables, whereas hs-CRP did not play a role. Here we demonstrate that IL-6 predicts neurocognitive functioning in adults with BD. BD may be a biological model for studying the relationship between inflammation and neurocognition in severe psychiatric disorders. Prospective studies at different mood phases of the disease must be conducted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.